Phase 2 Motor Neurone Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older
- People who have been diagnosed with ALS (also called Lou Gehrig's disease), confirmed using established medical guidelines known as the revised El Escorial criteria
- People whose lungs are working at 50% capacity or more, based on a breathing test called forced vital capacity (FVC)
- People who are able to swallow pills at the start of the study and are expected to continue to be able to do so throughout the study
- People who are taking ALS medications and have been on a stable, unchanged dose for at least 30 days before joining
- People who experience 4 or more muscle cramps per week during a 2-week check-in period before the study begins
Who may not be able to join:
- People who have had ALS for less than 5 years
- People who have had a tracheostomy, use a breathing machine inserted through the throat, or rely on a non-invasive breathing machine for more than 12 hours per day
- People who are pregnant or breastfeeding, people who are unable to give their own consent to participate, or people who are currently imprisoned
- People who are currently taking a medication called ranolazine, or who are taking or have recently taken any experimental (investigational) drug within the past 30 days or longer (confirm with trial site)
- People who have heart, liver, or kidney disease that is not well managed medically
- People who have a specific type of irregular heart rhythm finding on an ECG (called QTc interval prolongation above certain thresholds), a history of a condition called long QT syndrome, or who take medications known to affect heart rhythm in this way (confirm with trial site)
- People who have participated in an experimental drug trial within 30 days before the screening period
- People who are not on a stable dose of any muscle cramp medications — either the dose must have been unchanged for at least 30 days, or the person must have stopped taking those medications at least 30 days before joining the study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jeffrey Statland, MD, University of Kansas Medical Center
Phone: 913-945-9932
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Frequency of Treatment-Emergent Adverse Events; Tolerability of treatment assignment; Muscle cramp frequency; Muscle cramp severity; Muscle cramps impact on quality of life; Safety Lab Cystatin C; Safety Lab Estimated Glomerular Filtration Rate (eGFR); Safety Lab Alanine Transaminase (ALT); Safety Lab Aspartate Transferase (AST); Safety Lab Alkaline Phosphatase (ALP); Safety Lab Total Bilirubin
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.